TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23422376
Drug: Intramuscular ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ziprasidone (10 to 20 mg as required up to a maximum of 40 mg/d)
Study: 23422376
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol (5 mg every 4 to 8 hours to a maximum of 20 mg/d)
Study: 20615933
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (starting dose 50 mg eq., flexible dosing of 25, 50, 75, or 100 mg eq.)
Study: 19439457
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe with 400 microg folic acid
Study: 19439457
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Fe with 400 microg folic acid
Study: 19439457
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients (MuMS; 30 mg Fe, 400 microg folic acid, and other micronutrients)
Study: 16460693
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day citalopram
Study: 11680557
Drug: Combined individual
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined individual and family therapy
Study: 9326834
Drug: Xanomeline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline (25 mg t.i.d., 50 mg t.i.d., 75 mg t.i.d.)
Study: 8145176
Drug: Alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1 mg decrease every 3-7 days)
Study: 8145176
Drug: Alprazolam (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (long-term treatment for 5-12 months)
Study: 8145176
Drug: Alprazolam (tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (tapering and discontinuation)
Study: 2427808
Drug: 90 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/day nicardipine for 2 weeks
Study: 31405765
Drug: Vortioxetine 10
Normalized name: vortioxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10 mg QD for 5 weeks
Study: 31405765
Drug: Vortioxetine 20
Normalized name: vortioxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 20 mg QD for 5 weeks
Study: 31405765
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg QD for 5 weeks
Study: 23860985
Drug: Vasopressin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin (20 IU/CPR cycle) plus epinephrine (1 mg/CPR cycle)
Study: 23860985
Drug: Vasopressin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin (20 IU/CPR cycle) plus epinephrine (1 mg/CPR cycle) with postresuscitation shock treatment of stress-dose hydrocortisone (300 mg daily for 7 days maximum)
Study: 23860985
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo plus epinephrine (1 mg/CPR cycle)
Study: 23860985
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo plus epinephrine (1 mg/CPR cycle) with postresuscitation shock treatment of saline placebo
Study: 21523459
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative treatment group (B) - normal postoperative treatment or no treatment/self-management
Study: 18295613
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (30 minutes a day, 5 days a week for 4 weeks)
Study: 14594886
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg orally for 12 days)
Study: 11079645
Drug: Short-term vitamin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term vitamin C therapy (intravenous)
Study: 11079645
Drug: Long-term vitamin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term vitamin C therapy (oral)
Study: 31846631
Drug: 12-week daily
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week daily meal with fresh Hass avocado
Study: 21290836
Drug: Acupoint catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut embedding therapy
Study: 21528595
Drug: Pinaverium Bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium Bromide (50 mg, 3 times a day for 30 days)
Study: 19366490
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg x d DSR
Study: 15293131
Drug: Tablet-based 13C-urea
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet-based 13C-urea breath test
Study: 8295092
Drug: 0.15% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% chlorhexidine digluconate solution
Study: 8295092
Drug: Sodium benzoate-sodium
Normalized name: sodium benzoate-sodium phenylacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium benzoate-sodium bicarbonate (SBSB) compound
Study: 20651059
Drug: sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib 400 mg twice a day
Study: 14506483
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g low-fat (40%) spread fortified with 200 microg FA and a placebo tablet
Study: 14506483
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g low-fat placebo spread and a 200 microg FA tablet
Study: 14506483
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g low-fat placebo spread and a placebo tablet
Study: 10392865
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant urokinase (350,000 IU/hour for 6 hours, then 125,000 IU/hour for up to 18 hours)
Study: 10392865
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant urokinase (125,000 IU/hour for 6 hours, then 125,000 IU/hour for up to 18 hours)
Study: 10392865
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant urokinase
Study: 10392865
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant urokinase
Study: 10392865
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of recombinant urokinase
Study: 9373124
Drug: Conventional dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dual therapy (gentamicin 1.5% and cefuroxime 5.0%)
Study: 31492775
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training intervention for hypogonadal patients with testosterone replacement therapy
Study: 31492775
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training intervention for newly diagnosed males without testosterone replacement therapy
Study: 29980005
Drug: Single‐shot ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐shot ultrasound (US)‐guided ESP block with 20 ml 0.25% bupivacaine at the T4 vertebral level
Study: 29980005
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups provided with intravenous patient‐controlled analgesia device containing morphine
Study: 25364676
Drug: Hydrocortisone regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone regimen 1 (evening dose at 06.00-07.00 pm)
Study: 25364676
Drug: Hydrocortisone regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone regimen 2 (evening dose at 09.00-10.00 pm)
Study: 25364676
Drug: Prednisolone regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone regimen (evening dose at 10.00 pm)
Study: 18705533
Drug: Telmisartan monotherapy
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan monotherapy (10-160 mg)
Study: 18705533
Drug: Telmisartan plus
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan plus HCTZ (10-160 mg + 6.25-25 mg)
Study: 18705533
Drug: Telmisartan monotherapy
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan monotherapy (open-label)
Study: 12947329
Drug: Studies with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Studies with positive treatment effect
Study: 10593790
Drug: Hypoxic gas
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxic gas inhalation with aerosolized methacholine
Study: 10593790
Drug: Normoxic gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoxic gas inhalation with aerosolized methacholine
Study: 8722544
Drug: Erythromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1 g)
Study: 8722544
Drug: Clindamycin (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (0.6 g)
Study: 6097818
Drug: Gyno‐Travogen® vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gyno‐Travogen® vaginal tablets (300 mg isoconazole nitrate each)
Study: 6097818
Drug: Nizoral® tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizoral® tablets (200 mg ketoconazole each)
Study: 27900987
Drug: CEE 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.3 mg/micronized progesterone (MP) 100 mg daily (Group A)
Study: 27900987
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/MP 100 mg daily (Group B)
Study: 27900987
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/dydrogesterone 10 mg daily (Group C)
Study: 25248815
Drug: CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP levels >3 mg/L
Study: 25248815
Drug: CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP levels <1 mg/L
Study: 22763155
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU of vitamin D3 (pills)
Study: 20619140
Drug: Metoclopramide, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 20 mg intramuscularly injected three times a day.
Study: 7577891
Drug: Maize-based weaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize-based weaning food (before amylase treatment)
Study: 30171280
Drug: Cyclosporine 200
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 200 mg + Eltrombopag 50 mg
Study: 30171280
Drug: Cyclosporine 600
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 600 mg + Eltrombopag 50 mg
Study: 30171280
Drug: Eltrombopag 50
Normalized name: eltrombopag 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 50 mg alone
Study: 23777441
Drug: Single 2.5 mg/0.1 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2.5 mg/0.1 mL dose of subconjunctival bevacizumab immediately after surgery (group 1)
Study: 23777441
Drug: Double 2.5 mg/0.1 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double 2.5 mg/0.1 mL injection of subconjunctival bevacizumab (one immediately after surgery and the second 15 days after surgery) (group 2)
Study: 23777441
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (group 3)
Study: 12197843
Drug: Simethicone (105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone (105 mg t.d.s.)
Study: 26465985
Drug: Both vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vitamin D3 (1000 IU) and calcium (1200 mg)
Study: 26465985
Drug: Placebo (neither
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (neither agent)
Study: 20689455
Drug: Fruit, berry,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit, berry, and vegetable concentrate (FVC), Juice Plus+® (NSA LLC, Collierville, TN), supplement
Study: 19626400
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg three times per day)
Study: 16422738
Drug: Structured reminiscence
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured reminiscence group sessions held twice weekly for a six-week period
Study: 11700812
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1 g
Study: 11700812
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 3 g
Study: 11700812
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 3 g with additives ('Bio-C')
Study: 11700812
Drug: Placebo (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.03 g vitamin C)
Study: 9424970
Drug: Intraarticular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular morphine (small doses)
Study: 9424970
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intraarticular morphine and bupivacaine
Study: 9424970
Drug: Adrenaline addition,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline addition, tourniquet use, time interval between injection and tourniquet release
Study: 7962426
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with 200 x 10(6) purified paternal lymphocytes before pregnancy
Study: 3239463
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (no further treatment)
Study: 25575728
Drug: Montelukast (4mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (4mg daily for 5 days)
Study: 24085051
Drug: Topical regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical regimen (2% hydroquinone, 1% hydrocortisone and 0.05% tretinoin) with serial glycolic acid peeling
Study: 24085051
Drug: Topical regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical regimen (2% hydroquinone, 1% hydrocortisone, 0.05% tretinoin)
Study: 18439174
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus additional tilt training sessions
Study: 16714461
Drug: Theophylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (200 mg 30 minutes before contrast medium administration)
Study: 16714461
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg twice daily on the day of and the day before the examination)
Study: 16714461
Drug: Both agents
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both agents combined (theophylline and acetylcysteine)
Study: 15534843
Drug: Lipid lowering
Normalized name: Lipid lowering agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid lowering drug
Study: 11282901
Drug: Low-dose metoprolol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose metoprolol CR/XL (25 mg once daily)
Study: 21315352
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg once daily)
Study: 3324497
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nicergoline h.s.
Study: 3324497
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nicergoline b.i.d.
Study: 26503414
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 12 weeks
Study: 26503414
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 16 weeks
Study: 26503414
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 24 weeks
Study: 25237196
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 50 μg varicella-zoster virus glycoprotein E (gE) adjuvanted with AS01B
Study: 25237196
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of gE adjuvanted with AS01E
Study: 25237196
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of saline followed by 2 doses of gE/AS01B
Study: 25237196
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of saline
Study: 18809614
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with paclitaxel 200 mg/m² and carboplatin AUC 6 mg/mL/min every 3 weeks for four cycles
Study: 16278616
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg micronized 17beta‐estradiol daily
Study: 9860147
Drug: Enalapril (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (0.5 mg) at pH 5
Study: 9860147
Drug: Lisinopril (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (0.5 mg) at pH 6
Study: 9860147
Drug: Enalapril (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (0.06 mmol x l(‐1)) with cephradine (0.05 mmol x l(‐1))
Study: 9860147
Drug: Lisinopril (0.057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (0.057 mmol x l(‐1)) with cephradine (0.05 mmol x l(‐1))
Study: 7884114
Drug: Psyllium fiber
Normalized name: Konsyl Daily Psyllium Fiber
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium fiber (Metamucil) 3.4 g
Study: 2404487
Drug: 0.008% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.008% timolol ophthalmic solution
Study: 2404487
Drug: 0.25% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% timolol ophthalmic solution
Study: 25322473
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control group, N=65)
Study: 17383283
Drug: NT-proBNP (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP (highest quartile > or = 1170 ng/L for men, > or = 2150 ng/L for women)
Study: 15576015
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg administered orally under fasting conditions
Study: 15576015
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg administered orally under fed conditions
Study: 15576015
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg administered orally with food
Study: 7888977
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch treatment
Study: 3242578
Drug: Apomorphine (0.009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (0.009 mg kg‐1 subcutaneous route)
Study: 3242578
Drug: Yohimbine (0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (0.30 mg kg‐1 i.v. route)
Study: 28052841
Drug: Web-based guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based guided self-help intervention (cognitive-behavioral therapy and problem-solving therapy) in addition to usual care
Study: 23578686
Drug: Mitii training
Normalized name: Strychnos mitis whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitii training (20 weeks, 30 min daily)
Study: 16769956
Drug: No dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dopamine agonists
Study: 16769956
Drug: Potent D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent D3 receptor agonist
Study: 15315398
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (1000 mg/day total polyphenols)
Study: 11503008
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg, 3 times daily for 4 days)
Study: 11503008
Drug: DHEC (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEC (10 mg, administered alone)
Study: 9250182
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy - 30 fractions of 2 Gy for a total dose of 60 Gy in 6 weeks
Study: 8487006
Drug: Low-salt intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt intake (2.8 +/- 1.0 g day-1 of NaCl)
Study: 8487006
Drug: Salt supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt supplements (11.7 +/- 2.5 g day-1 of NaCl)
Study: 3661951
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of an opioid prior to methohexital and addition of lidocaine to the methohexital solution
Study: 29895330
Drug: Dapagliflozin (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (5-10 mg/day)
Study: 29895330
Drug: Sitagliptin (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (50-100 mg/day)
Study: 15175214
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 2% gel
Study: 16354850
Drug: Omega-3 PUFA-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA-rich supplement (400 kilocalories per day)
Study: 16354850
Drug: Omega-3 PUFA-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA-rich supplement
Study: 16354850
Drug: Omega-3 PUFA-nonrich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA-nonrich supplement
Study: 12552051
Drug: Droperidol 2.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 2.75 mg
Study: 12552051
Drug: Droperidol 5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 5.5 mg
Study: 12552051
Drug: Droperidol 8.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 8.25 mg
Study: 9448552
Drug: Zileuton 400
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton 400 mg 4 times daily
Study: 9448552
Drug: Zileuton 600
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 600 mg 4 times daily